Shelonitda S. Rose
Research Subjects
Shelonitda S. Rose has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Parvin Saidi
3 shared publicationsYaqoob Ali
2 shared publicationsA. Faiz
Division of Hematology, Department of Medicine, UMDNJ‐Robert Wood Johnson Medical School, New Brunswick, NJ
1 shared publicationAmit Kumar
1 shared publicationAshish A. Shah
UMDNJ/Robert Wood Johnson Medical School
1 shared publicationBarbara Maffei
UMDNJ-Robert Wood Johnson Medical School, New Brunswick, New Jersey
1 shared publication
Latest Publications
- 1 January 2009
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 337 (1) , 67-70
Deep Venous Thrombosis Caused by Inferior Vena Cava Atresia and Hereditary Thrombophilia
- 1 January 2009
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 337 (1) , 67-70
Deep Venous Thrombosis Caused by Inferior Vena Cava Atresia and Hereditary Thrombophilia
- 27 February 2008
- Published by Wiley in Haemophilia
- Vol. 14 (3) , 571-578
Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction
Intranasal desmopressin (IN-DDAVP) is used for home treatment of menorrhagia in women with inherited bleeding disorders. The effect of IN-DDAVP on laboratory haemostatic parameters in women with menorrhagia related to platelet dysfunction is unknown. We evaluated the effects of IN-DDAVP on haemostatic parameters in women with menorrhagia and platelet dysfunction and correlated them with menstrual flow. Eleven women (aged 18-45) with menorrhagia and haemostatic abnormalities had determination of von Willebrand factor antigen (VWF:Ag), von Willebrand factor ristocetin cofactor (VWF:RCo) activity, factor VIII coagulant activity (FVIII:C), platelet aggregation and platelet adenosine tri-phosphate (ATP) release pre-IN-DDAVP and 60-min post-IN-DDAVP. Eight of eleven women underwent platelet function analyzer (PFA-100) closure time determination with collagen/adrenaline and collagen/adenosine diphosphate cartridges pretreatment and post-treatment. IN-DDAVP was administered during two consecutive menstrual cycles. Menstrual flow was assessed during each cycle using a pictorial blood assessment chart. Treatment with IN-DDAVP resulted in elevated VWF levels and shortened PFA-100 closure time with significant inverse correlation between shortening of PFA-100 closure times and increases in VWF levels. There were also significant inverse correlations between changes in menstrual flow and changes in VWF:Ag (P = 0.02), VWF:RCo (P = 0.04) and FVIII:C (P = 0.006), following treatment. In vitro platelet aggregation and platelet ATP release response did not correct and did not correlate with changes in menstrual flow. Our results demonstrate a correlation between haemostatic parameters and menstrual flow following IN-DDAVP in women with menorrhagia and platelet dysfunction.
- 27 February 2008
- Published by Wiley in Haemophilia
- Vol. 14 (3) , 571-578
Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction
Intranasal desmopressin (IN-DDAVP) is used for home treatment of menorrhagia in women with inherited bleeding disorders. The effect of IN-DDAVP on laboratory haemostatic parameters in women with menorrhagia related to platelet dysfunction is unknown. We evaluated the effects of IN-DDAVP on haemostatic parameters in women with menorrhagia and platelet dysfunction and correlated them with menstrual flow. Eleven women (aged 18-45) with menorrhagia and haemostatic abnormalities had determination of von Willebrand factor antigen (VWF:Ag), von Willebrand factor ristocetin cofactor (VWF:RCo) activity, factor VIII coagulant activity (FVIII:C), platelet aggregation and platelet adenosine tri-phosphate (ATP) release pre-IN-DDAVP and 60-min post-IN-DDAVP. Eight of eleven women underwent platelet function analyzer (PFA-100) closure time determination with collagen/adrenaline and collagen/adenosine diphosphate cartridges pretreatment and post-treatment. IN-DDAVP was administered during two consecutive menstrual cycles. Menstrual flow was assessed during each cycle using a pictorial blood assessment chart. Treatment with IN-DDAVP resulted in elevated VWF levels and shortened PFA-100 closure time with significant inverse correlation between shortening of PFA-100 closure times and increases in VWF levels. There were also significant inverse correlations between changes in menstrual flow and changes in VWF:Ag (P = 0.02), VWF:RCo (P = 0.04) and FVIII:C (P = 0.006), following treatment. In vitro platelet aggregation and platelet ATP release response did not correct and did not correlate with changes in menstrual flow. Our results demonstrate a correlation between haemostatic parameters and menstrual flow following IN-DDAVP in women with menorrhagia and platelet dysfunction.
- 5 October 2007
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 22 (12) , 1775-1777
Cyanotic Congenital Heart Disease (CCHD) with Symptomatic Erythrocytosis
Secondary erythrocytosis of cyanotic congenital heart disease (CCHD) is pathologically different from primary erythrocytosis of polycythemia vera (PV). An association between elevated hematocrit and thrombosis has been established in PV patients, and treatment guidelines recommend maintaining hematocrit <45%. Although an association between elevated hematocrit and thrombosis has not been established in CCHD and secondary erythrocytosis, the current clinical practice is to phlebotomize these patients to hematocrit <65%. We report a 21-year-old woman with CCHD who presented with symptomatic erythrocytosis with numbness and tingling with hemoglobin 25.2 g/dl and hematocrit 75.8%. Her symptoms resolved with IV hydration. Other factors, including dehydration and iron deficiency, may precipitate hyperviscosity symptoms. The treatment is volume replacement and low-dose iron therapy, not phlebotomy. Repeated phlebotomy causes iron deficiency with microcytic erythrocytes, which increases the whole blood viscosity and, therefore, can potentially accentuate rather than decrease the risk for a cerebrovascular accident.
- 5 October 2007
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 22 (12) , 1775-1777
Cyanotic Congenital Heart Disease (CCHD) with Symptomatic Erythrocytosis
Secondary erythrocytosis of cyanotic congenital heart disease (CCHD) is pathologically different from primary erythrocytosis of polycythemia vera (PV). An association between elevated hematocrit and thrombosis has been established in PV patients, and treatment guidelines recommend maintaining hematocrit <45%. Although an association between elevated hematocrit and thrombosis has not been established in CCHD and secondary erythrocytosis, the current clinical practice is to phlebotomize these patients to hematocrit <65%. We report a 21-year-old woman with CCHD who presented with symptomatic erythrocytosis with numbness and tingling with hemoglobin 25.2 g/dl and hematocrit 75.8%. Her symptoms resolved with IV hydration. Other factors, including dehydration and iron deficiency, may precipitate hyperviscosity symptoms. The treatment is volume replacement and low-dose iron therapy, not phlebotomy. Repeated phlebotomy causes iron deficiency with microcytic erythrocytes, which increases the whole blood viscosity and, therefore, can potentially accentuate rather than decrease the risk for a cerebrovascular accident.
- Open Access
- 21 August 2006
- Published by Wiley in American Journal of Hematology
- Vol. 82 (3) , 245-246
Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor
- 21 August 2006
- Published by Wiley in American Journal of Hematology
- Vol. 82 (3) , 245-246
Open AccessTreatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor